Association Between Visfatin and Hepatic Steatosis in the General Population During Long-Term Follow-Up
Authors:
- Marion Flechtner-MorsMFMarion Flechtner-Mors
- Wolfgang KratzerWKWolfgang Kratzer
- Wolfgang KoenigWKWolfgang Koenig
- Bernhard Otto BoehmBBBernhard Otto Boehm
- Julian SchmidbergerJSJulian Schmidberger
- for the EMIL-Study groupFGfor the EMIL-Study group
- 27 May 2019
- journal article
- research article
- Published by Georg Thieme Verlag KG in Hormone and Metabolic Research
- Vol. 51 (09) , 602-607
Abstract
The aim of this study was to investigate any association between the adipose tissue-derived protein, visfatin, and non-alcoholic fatty liver disease (NAFLD) and its potential long-term impact on hepatic steatosis. A cross-sectional study including 2429 randomly selected subjects was performed in 2002. Later, 403 subjects were re-evaluated in 2013. Serum visfatin concentrations were determined by sandwich enzyme-linked immunosorbent assay. Phenotyping included abdominal ultrasonography, anthropometric data, and laboratory investigations. No association was found between circulating visfatin levels and the presence of NAFLD at baseline (2002: p=0.0967) or during follow-up (2013: p=0.1312). However, a significant increase in visfatin levels in relation to the level of steatosis was seen during follow-up (p<0.0001). During the more than 10-year follow-up, the metabolic status of the study subjects worsened, with a significant increase in body mass index (BMI) (p<0.0001), waist-to-hip ratio (p<0.0001), triglycerides (TG) (p<0.0001), low-density lipoprotein (p=0.0305), homeostasis model assessment (p<0.0001), and presence of diabetes (p<0.0001). This change was accompanied by an increase in serum visfatin levels, which showed a weak correlation with BMI (p<0.0001, r=0.27586) and presence of diabetes (p<0.0043, r=0.14188). A statistically significant correlation between leucocyte numbers and serum visfatin concentration (p<0.0001, r=0.25615) was found. We found no association between visfatin levels and the presence or absence of NAFLD or the degree of hepatic fatty infiltration at baseline. There was a strong correlation between serum visfatin concentrations and the number of leucocytes, which may suggest a proinflammatory role for visfatin.Keywords
This publication has 24 references indexed in Scilit:
- Visfatin/NAMPT: A Multifaceted Molecule with Diverse Roles in Physiology and PathophysiologyAnnual Review of Nutrition, 2012
- Visfatin Levels in Nonalcoholic Fatty Liver DiseaseJournal of Clinical Laboratory Analysis, 2012
- What's new in our understanding of the role of adipokines in rheumatic diseases?Nature Reviews Rheumatology, 2011
- Adipokines in inflammation and metabolic diseaseNature Reviews Immunology, 2011
- Evaluation of diffuse liver steatosis by ultrasound, computed tomography, and magnetic resonance imaging: which modality is best?Clinical Imaging, 2009
- Increased plasma visfatin levels in subjects with the metabolic syndromeEuropean Journal of Clinical Investigation, 2007
- Adipokines and cytokines in non‐alcoholic fatty liver diseaseAlimentary Pharmacology & Therapeutics, 2007
- Serum visfatin in relation to visceral fat, obesity, and type 2 diabetes mellitus in Asian IndiansMetabolism, 2007
- Role of Radiologic Modalities in the Management of Non-alcoholic SteatohepatitisClinics in Liver Disease, 2007
- The Adipokine Visfatin is Markedly Elevated in Obese ChildrenJournal of Pediatric Gastroenterology and Nutrition, 2006